How the triglyceride–glucose (TyG) index relates to heart artery imaging in non‑diabetic adults with early coronary artery disease
Impact of Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients
This study will see if the triglyceride–glucose (TyG) index helps explain angiographic patterns in non‑diabetic adults who develop coronary artery disease at younger ages.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT07154186 on ClinicalTrials.gov |
What this trial studies
This is an observational study of non‑diabetic patients with premature coronary artery disease confirmed by coronary angiography. Investigators will calculate the TyG index from fasting triglyceride and glucose levels and compare it with angiographic lesion patterns and severity. Patients with known diabetes, prior revascularization, severe liver/kidney dysfunction, malignancy, autoimmune or systemic inflammatory disease, or current triglyceride‑lowering therapy are excluded. The work is conducted at Sohag University and aims to link a low‑cost blood marker of insulin resistance to early atherosclerotic changes on angiography.
Who should consider this trial
Good fit: Adults aged 18 or older who are non‑diabetic with angiographically confirmed premature coronary artery disease (before age 55 in men and 65 in women), without prior coronary revascularization and without severe hepatic or renal dysfunction.
Not a fit: People with known diabetes, prior coronary revascularization, severe liver or kidney disease, active cancer, autoimmune or systemic inflammatory disorders, or those already on triglyceride‑lowering drugs are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the TyG index could offer a simple, low‑cost blood marker to help identify insulin‑resistance–related artery disease patterns and guide earlier management in non‑diabetic patients.
How similar studies have performed: Prior observational studies have reported links between higher TyG index values and more severe coronary atherosclerosis, but prospective and interventional evidence remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years old. * Both sexes. * Non-diabetic patients \[no history of diabetes, hemoglobin A1C (HbA1C) \< 6.5%, fasting glucose \< 126 mg/dL\]. * Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography. Exclusion Criteria: * Known diabetes mellitus (type 1 or type 2). * Previous history of coronary revascularization. * Severe hepatic or renal dysfunction \[alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)\< 30 mL/min/1.73 m²\]. * Malignant disease, autoimmune disease, or systemic inflammatory disorders. * Current use of triglyceride-lowering medications.
Where this trial is running
Sohag
- Sohag University — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Remon S Adly, MD
- Email: remonsaleh@yahoo.com
- Phone: 00201221878986
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.